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Dear Editor, I read with interest the study by Rimaz et al. (1) which showed a statistically significant reduction in visual analogue pain scores and morphine consumption in a double blind randomised setting with 25 patients in each wing. This is not the first study to suggest that in tackling the complex mechanism of post-burn hypersensitivity, as yet not fully understood but thought to be similar to post-operative pain hypersensitivity; analgesics with different but synergistic effects may prove superior to opioid an-algesia alone (2, 3). Although in common use for neuro-pathic pain worldwide gabapentin has only relatively re-cently been taken up by plastic surgeons for use in acute burn pain both pre and post-surgical debridement. Al-though the study undoubtedly shows promising results in terms of a significant decrease in both pain scores and morphine consumption, there are some difficulties which must be addressed prior to gabapentin potentially becoming an accepted adjunct to opioid analgesia in the treatment of acute burns pain. As is often the case with 
the introduction of adjuvant drug treatment studies are difficult to compare due to the inherent variability of drug dosage, regimen, and use of adjuvant drugs and length of treatment. A similar study looking at the effects of gabapentin on morphine consumption in burns pa-tients by Cuignet et al. (2), although reaching the same overall conclusions as Rimaz et al. (1) used a very differ-ent dosing regimen; a single dose of 1200mg gabapentin pre-operatively (1) and 2400mg daily from burn day 3-24 and results recorded for 21 days pre and post-surgical de-bridement (2) respectively. Additionally, in a further case series using gabapentin for acute burn pain Gray et al. (3) used regimens as varied as 1000mg four times per day with concurrent oxycodone and 300mg three times per day are described. Therefore although several studies have now shown ga-bapentin to be a beneficial addition to an opioid analgesia regimen in burns patients (1-3) what is required is collab-orative research effort in order to determine the lowest possible dose of gabapentin to achieve maximal pain re-lief but with minimal side effects. This will allow a future 
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systematic review with significant power to change rec-
ommended practice should future research continue to 
produce positive results. Although Rimaz et al. (1) found 
no side effects with the 1200mg single pre-operative dose 
of gabapentin, it must not be forgotten that gabapentin 
is a drug which can cause significant side effects even if 
only used for a short period of time, especially at the rela-
tively high doses recommended by Cuignet et al. (2) Mul-
ticentre studies of gabapentin in post-herpetic neuralgia 
and painful diabetic neuropathy have shown significant 
side effects reporting day-time somnolence of up to 27% 
(4) and dizziness at 24% (5) which must be balanced with 
the potential analgesic benefit of gabapentin in burns 
patients. In the interests of burns patients world-wide 
is it hoped that further collaborative research will fol-
low promptly to advance a treatment which, although 
currently in its infancy, has the potential to alleviate the 
significant pain that many such patients currently suffer.
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